Clarivate Plc

As of October 3, 2025, Clarivate Plc's technical trend is bearish, indicated by negative MACD, Bollinger Bands, and moving averages, with a year-to-date return of -25.20% compared to the S&P 500's 14.18%.

As of October 3, 2025, Clarivate Plc's trend has shifted to bearish with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -23.43% compared to the S&P's 14.18%.

As of October 3, 2025, Clarivate Plc's trend has shifted to bearish with weak strength, underperforming the S&P 500 significantly, showing a year-to-date return of -23.43% compared to the S&P's 14.18%.

As of September 12, 2025, Clarivate Plc shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly over the past year and five years.

As of February 27, 2024, Clarivate Plc's valuation has shifted from fair to risky due to overvaluation indicators and significant underperformance compared to the S&P 500, with a year-to-date return of -19.09% and a three-year decline of 61.12%.

As of February 27, 2024, Clarivate Plc is considered overvalued and risky due to poor financial ratios, including a negative return on equity and disappointing stock performance, especially when compared to its peers like Medpace and Genpact.

As of April 30, 2025, Clarivate Plc's trend is mildly bearish, with daily moving averages signaling bearishness, while mixed indicators suggest a cautious approach due to prevailing bearish signals.

Clarivate Plc is an information services and analytics company focused on scientific research, intellectual property, and life sciences, with recent net sales of $594 million and a market cap of approximately $2.9 billion. The company reported a net profit loss of $104 million for March 2025.

As of Jun 18, Clarivate Plc has a market capitalization of 2,896.29 million, with net sales of 2,529.20 million and a net profit of -665.60 million over the latest four quarters.